Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine filings document the regulatory and financial record of a clinical-stage biopharmaceutical company developing hematologic disease therapies. Its Form 8-K disclosures cover quarterly and annual financial results, corporate updates, clinical-program materials for bitopertin, DISC-0974 and DISC-3405, and FDA communications related to the bitopertin New Drug Application for erythropoietic protoporphyria.
The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting items. Material-event reports describe Regulation FD presentations, operating runway disclosures, restructuring actions following regulatory developments, and risk-related statements around clinical trials, regulatory pathways, research spending and capital resources.
Disc Medicine, Inc. (IRON) – CEO Form 4 filing dated 07/08/2025
Chief Executive Officer John D. Quisel disclosed an exercise-and-sell transaction executed on 07/03/2025 under a Rule 10b5-1 trading plan adopted on 02/13/2025.
- Option exercise (Code M): 5,200 options exercised at $9.86, converting into 5,200 common shares.
- Open-market sale (Code S): the same 5,200 shares sold at a $55.0874 weighted-average price (range $55.00–$55.26), generating ≈ $0.29 million gross proceeds.
- Post-transaction ownership: 161,828 common shares held directly and 150,175 options remaining.
- The underlying option grant (09/13/2031 expiration) vests in 48 equal monthly tranches that began on 09/01/2021.
The filing represents a relatively small (< 4%) reduction in Quisel’s equity stake and appears routine, given the pre-arranged 10b5-1 plan. No company fundamentals were released.
Disc Medicine, Inc. (NASDAQ: IRON) – Form 4 insider transaction
Chief Financial Officer Jean M. Franchi filed a Form 4 reporting the sale of 2,000 shares of common stock on 16 June 2025. The shares were sold under a previously adopted Rule 10b5-1 trading plan dated 10 March 2025 at a weighted-average price of $52.2594 per share, with individual trades executed between $51.79 and $52.61. Following the sale, Franchi’s direct beneficial ownership stands at 67,530 common shares.
No derivative securities were reported in this filing, and there were no acquisitions of additional shares or option exercises. The filing confirms that the transaction was executed directly (ownership code “D”).
The disposal represents roughly 3% of the reporting person’s post-transaction holdings and does not materially affect the company’s share count. While investors track Form 4 filings to assess insider sentiment, the modest size and pre-planned nature of this sale limit its informational weight.